ND2

General Information


DRACP ID  DRACP01105

Peptide Name   ND2

Sequence  GLFDIVKGIKSLF

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Hep-G2 Hepatoblastoma; Hepatoblastoma Blastoma IC50=72.00±4.51 µg/mL MTT assay 24h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Vero: IC50=48.67±1.76 µg/mL; THLE-3: IC50=58.83±0.83 µg/mL

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01105

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C70H113N15O17

Absent amino acids  ACEHMNPQRTWY

Common amino acids  FGIKL

Mass  165099

Pl  9.54

Basic residues  2

Acidic residues  1

Hydrophobic residues  7

Net charge  1

Boman Index  834

Hydrophobicity  103.85

Aliphatic Index  142.31

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Hybrid Anticancer Peptides DN1 and DN4 Exert Selective Cytotoxicity Against Hepatocellular Carcinoma Cells by Inducing Both Intrinsic and Extrinsic Apoptotic Pathways

Doi 10.1007/s10989-021-10288-8

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.